Are Billions in Peptides Up for Grabs or at Stake?

It depends on whom you work for...Two important highlights:

1. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize

- On April 01, 2026, FDA clarifies policies for compounders. The FDA stated that a compounded drug product is considered essentially a copy of a commercially available drug product if

· The compounded drug product contains the same APIs as two or more commercially available drug products in the same, similar, or easily substitutable strength and

· The commercially available drug product can be used (regardless of how it is labeled) by the same route of administration prescribed for the compounded drug product, unless there is documentation of a prescriber determination of a significant difference  

- This clarification will likely put limitation to many 503A and 503B compounders making GLP-1s which are now viewed by FDA as potentially copies of commercially available drugs even if it may meet the definition of "pharmacy compounding" (see https://www.wynngateconsulting.com/post/drug-shortages-and-human-drug-compounding-a-quick-review)

- For 503B, at this time it implies "no more compounding of GLP-1 as it is not on the drug shortage list”

- For 503A, this implies less compounding of GLP-1 copies as FDA only allows 503A compounders to fill four or fewer prescriptions of commercially available copies per calendar month

- For drug manufacturers of GLP-1's, this may indicate a shift of cash flow back now that FDA has clarified the limitation of compounding GLP-1's

- And then there are "black market" sellers who make GLP-1 and labeled them as R&D or not for human use but intentionally sell them for human use (see unapproved drug charges on https://www.linkedin.com/posts/binh-nguyen-a77046190_gear-isle-issues-voluntary-nationwide-recall-activity-7448244047732822017-6sqW?utm_source=share&utm_medium=member_desktop&rcm=ACoAACzbMnsBy7xCjkg3teALCJ5qHc90nksj45g)

- However, FDA still leaves some room for compounders by stating that active ingredients used are considered essentially copies if they are within 10% of the strengths of the respective commercially available drug products --> this implies that compounding of actives beyond 10% may not be considered as copies?!

- In addition, FDA does not have jurisdiction over the practice of medicine and therefore it depends on prescriber’s determination to document the significant differences between compounded drugs vs. commercially available drugs.

2. With an escalation from HHS Secretary Robert F. Kennedy Jr., many restricted peptides may return to Category 1 status for compounding?  The FDA is having a formal pharmacy compounding advisory meeting (July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee - 07/23/2026 | FDA) where 7 peptides will be discussed covering various important therapeutic indications below. This is a HUGE opportunity if these 7 peptides make it onto the Category 1 503A bulk list (Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act | FDA) for compounding

Bulk Drug Substance	Uses Evaluated
BPC-157	Ulcerative colitis
KPV	Wound healing and inflammatory conditions
TB-500	Wound healing
MOTs-C	Obesity and osteoporosis
Emideltide	Opioid withdrawal, chronic insomnia, and narcolepsy
Semax	Cerebral ischemia, migraine, and trigeminal neuralgia
Epitalon	Insomnia